Midwest Institute for Clinical Research

Executive Summary

Midwest Institute for Clinical Research (MICR) is a private clinical research organization headquartered in Indianapolis, founded in 1998. The company specializes in conducting paid clinical trials for pharmaceutical and medical device companies, with a core focus on volunteer recruitment and trial implementation. By connecting volunteers with studies, MICR supports the development of new therapies across various therapeutic areas. Operating as a site management organization, it leverages its established infrastructure and local patient networks to deliver efficient trial execution. While the company has not disclosed funding or valuation, its long-standing presence since 1998 suggests stability and repeat business from sponsors. The CRO market remains competitive, but MICR's niche focus on clinical trial execution positions it well to benefit from increasing R&D outsourcing by pharmaceutical companies. Looking ahead, MICR's growth will depend on its ability to secure new trial contracts and expand capacity. The company may also explore decentralized trial capabilities to adapt to industry trends. However, as a private firm with limited public information, the investment thesis relies on broader sector tailwinds. The company's conviction score is moderate, reflecting its established operations but lack of visible catalysts or scale. Key risks include competition from larger CROs and regulatory changes affecting trial recruitment.

Upcoming Catalysts (preview)

• Q4 2026New multi-year contracts with top pharma sponsors40% success
• Q2 2027Expansion of clinical trial capacity via new facilities30% success
• Q1 2027Adoption of decentralized trial technologies to increase patient recruitment25% success